

ASCO Guidelines Summary

1

Administration of bisphosphonate as adjuvant therapy should be considered in,
- postmenopausal breast cancer patients as well as premenopausal who have menopause induced by ovarian suppression deemed candidates for systematic therapy.
- final decision takes in consideration risk of recurrence, risk/benefits of therapy

2

Either Zoledronic acid or Clodronate can be used

3

The results of Denosumab look promising, however, data is insufficient at this time to make recommendations

4

Dose recommendations,
Zoledronic acid 4 mg iv every 6 month for 3 to 5 years or Clodronate orally 1600 mg daily for 2 to 3 years. Different duration may be considered

5

Specific definitions of post menopausal status, please refer to the article

6

ONJ risk assessment and dental clearance must be obtained prior to starting bisphosphonate therapy.